Arroyo-Currás Netzahualcóyotl, Ortega Gabriel, Copp David A, Ploense Kyle L, Plaxco Zoe A, Kippin Tod E, Hespanha João P, Plaxco Kevin W
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland 21205, United States.
Department of Chemistry and Biochemistry, Center for Bioengineering, Center for Control, Dynamical Systems, and Computation, Department of Psychological and Brain Sciences, and The Neuroscience Research Institute and Department of Molecular, Cellular, and Developmental Biology, University of California Santa Barbara, Santa Barbara, California 93106, United States.
ACS Pharmacol Transl Sci. 2018 Oct 5;1(2):110-118. doi: 10.1021/acsptsci.8b00033. eCollection 2018 Nov 9.
By, in effect, rendering pharmacokinetics an experimentally adjustable parameter, the ability to perform feedback-controlled dosing informed by high-frequency in vivo drug measurements would prove a powerful tool for both pharmacological research and clinical practice. Efforts to this end, however, have historically been thwarted by an inability to measure in vivo drug levels in real time and with sufficient convenience and temporal resolution. In response, we describe a closed-loop, feedback-controlled delivery system that uses drug level measurements provided by an in vivo electrochemical aptamer-based (E-AB) sensor to adjust dosing rates every 7 s. The resulting system supports the maintenance of either constant or predefined time-varying plasma drug concentration profiles in live rats over many hours. For researchers, the resultant high-precision control over drug plasma concentrations provides an unprecedented opportunity to (1) map the relationships between pharmacokinetics and clinical outcomes, (2) eliminate inter- and intrasubject metabolic variation as a confounding experimental variable, (3) accurately simulate human pharmacokinetics in animal models, and (4) measure minute-to-minute changes in a drug's pharmacokinetic behavior in response to changing health status, diet, drug-drug interactions, or other intrinsic and external factors. In the clinic, feedback-controlled drug delivery would improve our ability to accurately maintain therapeutic drug levels in the face of large, often unpredictable intra- and interpatient metabolic variation. This, in turn, would improve the efficacy and safety of therapeutic intervention, particularly for the most gravely ill patients, for whom metabolic variability is highest and the margin for therapeutic error is smallest.
通过实际上将药代动力学转变为一个可通过实验调节的参数,利用高频体内药物测量进行反馈控制给药的能力将被证明是药理学研究和临床实践的有力工具。然而,为此所做的努力在历史上一直受到无法实时、方便且具有足够时间分辨率地测量体内药物水平的阻碍。作为回应,我们描述了一种闭环反馈控制给药系统,该系统使用基于体内电化学适体(E-AB)传感器提供的药物水平测量结果,每7秒调整一次给药速率。由此产生的系统能够在数小时内支持维持活鼠体内恒定或预定义的随时间变化的血浆药物浓度曲线。对于研究人员而言,由此对药物血浆浓度实现的高精度控制提供了前所未有的机会:(1)描绘药代动力学与临床结果之间的关系;(2)消除受试者间和受试者内的代谢变异作为一个混杂的实验变量;(3)在动物模型中准确模拟人体药代动力学;(4)测量药物药代动力学行为因健康状况、饮食、药物相互作用或其他内在和外在因素变化而产生的每分钟变化。在临床上,反馈控制给药将提高我们在面对患者体内和患者间巨大且通常不可预测的代谢变异时准确维持治疗药物水平的能力。这反过来将提高治疗干预的有效性和安全性,特别是对于病情最严重的患者,他们的代谢变异性最高,治疗误差范围最小。